Skip to main content

Advertisement

Log in

A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Infliximab is a chimeric monoclonal antibody. Published studies indicate that its use in patients with rheumatoid arthritis can be efficient in providing long-term benefits. The aim of this study is to evaluate the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis. A systematic review was performed to search for randomized clinical trials that compared intravenous administration of 3 mg/kg body weight infliximab or placebo in patients concomitantly using methotrexate. Only studies of moderate or high quality were included. A meta-analysis was conducted to assess the efficacy (based on changes of American College of Rheumatology (ACR) criteria) and the safety (based on serious adverse events, serious infections, malignancy, and deaths) of infliximab use. Withdrawals due to adverse events or lack of efficacy were also evaluated in both infliximab-treated and control groups. Seven trials met the inclusion criteria, comprising 2,129 patients. In the efficacy meta-analysis, a greater number of infliximab-treated patients relative to those in the placebo group achieved ACR20, ACR50, and ACR70 values from 14 weeks to 2 years of treatment. For safety analysis, there were no statistically significant differences between the groups. Withdrawals due to adverse events were higher in the infliximab group relative to the placebo group, and withdrawals due to lack of efficacy were higher in the placebo group relative to the infliximab-treated group. This meta-analysis shows a higher efficacy of infliximab relative to placebo without significant safety differences between the infliximab-treated and control groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Tugwell P (2000) Pharmacoeconomics of drug therapy for rheumatoid arthritis. Rheumatology (Oxford) 39(Suppl 1):43–47

    Google Scholar 

  2. Moss ML, Sklair-Tavron L, Nudelman R (2008) Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol 4(6):300–309

    Article  CAS  PubMed  Google Scholar 

  3. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410):675–681

    Article  CAS  PubMed  Google Scholar 

  4. Bértolo M, Brenol C, Schainberg C, Neubarth F (2007) Atualização do consenso brasileiro no diagnóstico e tratamento da artrite reumatóide. Rev Bras Reumatol 47(3):151–159

    Google Scholar 

  5. Fernandez-Nebro A, Irigoyen MV, Urena I, Belmonte-Lopez MA, Coret V, Jimenez-Nunez FG et al (2007) Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis. J Rheumatol 34(12):2334–2342

    CAS  PubMed  Google Scholar 

  6. Kanbe K, Inoue K, Inoue Y, Suzuki Y (2008) Histological changes in bone marrow after treatment of infliximab for rheumatoid arthritis. Clin Rheumatol 27(4):497–501

    Article  PubMed  Google Scholar 

  7. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354(9194):1932–1939

    Article  CAS  PubMed  Google Scholar 

  8. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D et al (2005) Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 52(4):1020–1030

    Article  CAS  PubMed  Google Scholar 

  9. Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR et al (2004) Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 63:149–155

    Article  CAS  PubMed  Google Scholar 

  10. Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358(9285):903–911

    Article  CAS  PubMed  Google Scholar 

  11. Silva RG, Vannucci AB, Latorre LC, Zerbini CAF (2003) Artrite reumatóide. Rev Bras Med 60(8):554–577

    Google Scholar 

  12. Zintzaras E, Dahabreh IJ, Giannouli S, Voulgarelis M, Moutsopoulos HM (2008) Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. Clin Ther 30(11):1939–1955

    Article  CAS  PubMed  Google Scholar 

  13. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50(11):3432–3443

    Article  CAS  PubMed  Google Scholar 

  14. Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y et al (2006) A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol 33(1):37–44

    CAS  PubMed  Google Scholar 

  15. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343(22):1594–1602

    Article  CAS  PubMed  Google Scholar 

  16. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S et al (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67(8):1096–1103

    Article  CAS  PubMed  Google Scholar 

  17. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P et al (2006) The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 54(4):1075–1086

    Article  CAS  PubMed  Google Scholar 

  18. Zhang F-C, Hou Y, Huang F, Wu D-H, Bao C-D, Ni L-Q et al (2006) Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China. APLAR J Rheumatol 9(2):127–130

    Article  Google Scholar 

  19. Taylor PC, Steuer A, Gruber J, Cosgrove DO, Blomley MJ, Marsters PA et al (2004) Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 50(4):1107–1116

    Article  CAS  PubMed  Google Scholar 

  20. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12

    Article  CAS  PubMed  Google Scholar 

  21. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6):727–735

    Article  CAS  PubMed  Google Scholar 

  22. Hakkinen A, Kautiainen H, Hannonen P, Ylinen J, Makinen H, Sokka T (2006) Muscle strength, pain, and disease activity explain individual subdimensions of the Health Assessment Questionnaire disability index, especially in women with rheumatoid arthritis. Ann Rheum Dis 65(1):30–34

    Article  CAS  PubMed  Google Scholar 

  23. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J (2006) Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 11(2):193–206

    Article  PubMed  Google Scholar 

  24. Quinn MA, Conaghan PG, O'connor PJ, Karim Z, Greenstein A, Brown A et al (2005) Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52(1):27–35

    Article  CAS  PubMed  Google Scholar 

  25. Smolen JS, van der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E et al (2006) Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 54(3):702–710

    Article  CAS  PubMed  Google Scholar 

  26. Food and Drug Administration (2006) Arthritis Drugs Advisory Committee: Safety update on TNF antagonists: infliximab and etanercept. http://wwwfdagov/medwatch/SAFETY/2006/May_PIs/Remicade_PIpdfhttp://wwwfdagov/medwatch/SAFETY/2006/May_PIs/Remicade_PIpdf

  27. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54(8):2368–2376

    Article  CAS  PubMed  Google Scholar 

  28. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098–1104

    Article  CAS  PubMed  Google Scholar 

  29. van der Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F et al (2006) Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther 8(4):R112

    Article  Google Scholar 

  30. Pavelka K, Jarosova K, Suchy D, Senolt L, Chroust K, Dusek L et al (2009) Increasing the infliximab dose in rheumatoid arthritis patients: a randomized, double blind study failed to confirm its efficacy. Ann Rheum Dis 68:1285–1289

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosures

Astrid Wiens, none; Cassyano Januario Correr, none; Rafael Venson, none; Mônica Cavichiolo Grochocki, none; Michel Fleith Otuki, none; Roberto Pontarolo, none.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Cassyano Januário Correr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wiens, A., Correr, C.J., Venson, R. et al. A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis. Clin Rheumatol 28, 1365–1373 (2009). https://doi.org/10.1007/s10067-009-1233-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-009-1233-9

Keywords

Navigation